Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>The U.S. House passed the Biosecure Act, mandating U.S. pharma firms to cut ties with specific Chinese biotechs by 2032.</li>
<li>This opens opportunities for Indian CDMOs, positioning them as viable alternatives due to geopolitical alignment and regulatory quality.</li>
<li>India’s CDMOs could see substantial growth, benefiting from increased global diversification efforts away from China.</li>
</ul>


The U.S. House passed the Biosecure Act, mandating U.S. pharma firms to cut ties with specific Chinese biotechs by 2032.
This opens opportunities for Indian CDMOs, positioning them as viable alternatives due to geopolitical alignment and regulatory quality.
India’s CDMOs could see substantial growth, benefiting from increased global diversification efforts away from China.


The US Biosecure Act: A Boon for Indian CDMO Players?

<ul>
<li>SEBI has overhauled F&amp;O eligibility criteria, introducing stricter norms for stock inclusion and exclusion for more active stocks. </li>
<li>As per calculation, New criteria will include 80 stocks and exclude 18 to 23, impacting market liquidity and stability.</li>
<li>This will lead to the creation of a more robust, transparent, and liquid for the F&amp;O Market.</li>
</ul>


SEBI has overhauled F&amp;O eligibility criteria, introducing stricter norms for stock inclusion and exclusion for more active stocks. 
As per calculation, New criteria will include 80 stocks and exclude 18 to 23, impacting market liquidity and stability.
This will lead to the creation of a more robust, transparent, and liquid for the F&amp;O Market.


SEBI's F&O Criteria Revision & Its Impact

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analysed the earning revision of component stocks of MS-India in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Hindalco Industries, Adani Enterprises, Grasim Industries, Reliance Industries, Axis Bank, ICICI Bank, HDFC Bank, Tata Motors Passenger Vehicles.</li>
</ul>


We analysed the earning revision of component stocks of MS-India in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Hindalco Industries, Adani Enterprises, Grasim Industries, Reliance Industries, Axis Bank, ICICI Bank, HDFC Bank, Tata Motors Passenger Vehicles.


MS-India Index Earning Revision (Aug): Hindalco Industries, Adani Enterprises, Grasim Industries

Equity Bottom-Up

<ul>
<li>Symbiotec Pharmalab is launching a INR 1,757 crore IPO, offering specialised pharmaceutical APIs, nutritional ingredients and complex injectable products.</li>
<li>The company has built a global presence in corticosteroid and steroid hormone APIs, with a significant share of revenue coming from international markets.</li>
<li>The IPO provides public investors access to a niche pharmaceutical manufacturing platform, but earnings sustainability depends on managing product concentration, regulatory compliance and global demand cycles.</li>
</ul>


Symbiotec Pharmalab is launching a INR 1,757 crore IPO, offering specialised pharmaceutical APIs, nutritional ingredients and complex injectable products.
The company has built a global presence in corticosteroid and steroid hormone APIs, with a significant share of revenue coming from international markets.
The IPO provides public investors access to a niche pharmaceutical manufacturing platform, but earnings sustainability depends on managing product concentration, regulatory compliance and global demand cycles.


Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

<ul>
<li>The Closing Auction Session (CAS) kicked off on 3 August for Indian stocks that are part of the Futures &amp; Options (F&amp;O) segment of the market.</li>
<li>Daily total turnover in CAS since launch has averaged around US$128m. In comparison, global passives will need to trade around US$4bn of F&amp;O stocks at the CAS on 31 August.</li>
<li>There could be large moves in affected stocks in the lead up to the CAS on Monday, followed by more large moves at CAS, and a potential reversal on Tuesday. </li>
</ul>


The Closing Auction Session (CAS) kicked off on 3 August for Indian stocks that are part of the Futures &amp; Options (F&amp;O) segment of the market.
Daily total turnover in CAS since launch has averaged around US$128m. In comparison, global passives will need to trade around US$4bn of F&amp;O stocks at the CAS on 31 August.
There could be large moves in affected stocks in the lead up to the CAS on Monday, followed by more large moves at CAS, and a potential reversal on Tuesday. 


India: Key CAS Test on Monday as Global Index Rebalances

India

Laurus Labs is a research-driven, integrated pharmaceutical and biotechnology company specializing in Active Pharmaceutical Ingredients (APIs), generic formulations, and Contract Development and Manufacturing Organization (CDMO) services. The company is a global leader in antiretroviral (ARV) APIs and has diversified into oncology, cardiovascular, and biotechnology segments. Laurus Labs is headquartered in Hyderabad, India, and was founded in 2005.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laurus Labs (LAURUS IN)

The US Biosecure Act: A Boon for Indian CDMO Players?

The Biosecure Act passed by the U.S. House could boost Indian CDMOs as alternative to Chinese biotechs by 2032, leading to potential growth...

Nimish Maheshwari

SEBI's F&O Criteria Revision & Its Impact

SEBI introduces stricter F&O eligibility criteria, impacting market liquidity and stability by including 80 stocks and excluding 18 to 23. #SEBI...

Nimish Maheshwari

MS-India Index Earning Revision (Aug): Hindalco Industries, Adani Enterprises, Grasim Industries

We analyzed MS-India's consensus for Aug 2026 and highlighted changes of EPS in Hindalco Industries (HNDL IN), Adani Enterprises (ADE/S IN), Grasim...

Ke Yan, CFA, FRM

Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform

Symbiotec Pharmalab combines leadership in steroidal APIs with complex injectables and biotech capabilities, offering global growth opportunities...

Nimish Maheshwari

India: Key CAS Test on Monday as Global Index Rebalances

CAS kicked off on 3 August and turnover has averaged US$128m. A global index rebalance on Monday will require passives to trade many multiples of...

Brian Freitas

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

The US Biosecure Act: A Boon for Indian CDMO Players?

​The Biosecure Act passed by the U.S. House could boost Indian CDMOs as alternative to Chinese biotechs by 2032, leading to potential growth...

Nimish Maheshwari

SEBI's F&O Criteria Revision & Its Impact

​SEBI introduces stricter F&O eligibility criteria, impacting market liquidity and stability by including 80 stocks and excluding 18 to 23. #SEBI...

Nimish Maheshwari

MS-India Index Earning Revision (Aug): Hindalco Industries, Adani Enterprises, Grasim Industries

We analyzed MS-India's consensus for Aug 2026 and highlighted changes of EPS in Hindalco Industries (HNDL IN), Adani Enterprises (ADE/S IN), Grasim...

Ke Yan, CFA, FRM

Symbiotec Pharmalab IPO Review: A Niche Steroidal API Platform

Symbiotec Pharmalab combines leadership in steroidal APIs with complex injectables and biotech capabilities, offering global growth opportunities...

Nimish Maheshwari

India: Key CAS Test on Monday as Global Index Rebalances

CAS kicked off on 3 August and turnover has averaged US$128m. A global index rebalance on Monday will require passives to trade many multiples of...

Brian Freitas

The Biosecure Act passed by the U.S. House could boost Indian CDMOs as alternative to Chinese biotechs by 2032, leading to potential growth...

SEBI introduces stricter F&O eligibility criteria, impacting market liquidity and stability by including 80 stocks and excluding 18 to 23. #SEBI...